Modulation of plasma protein binding and in vivo liver cell uptake of phosphorothioate oligodeoxynucleotides by cholesterol conjugation

AUTOR(ES)

Bijsterbosch, Martin K.

FONTE

Oxford University Press

RESUMO

Several studies have shown improved efficacy of cholesteryl-conjugated phosphorothioate antisense oligodeoxynucleotides. To gain insight into the mechanisms of the improved efficacy in vivo, we investigated the disposition of ISIS-9388, the 3′-cholesterol analog of the ICAM-1-specific phosphoro­thioate oligodeoxynucleotide ISIS-3082, in rats. Intravenously injected [3H]ISIS-9388 was cleared from the circulation with a half-life of 49.9 ± 2.2 min (ISIS-3082, 23.3 ± 3.8 min). At 3 h after injection, the liver contained 63.7 ± 3.3% of the dose. Compared to ISIS-3082, the hepatic uptake of ISIS-9388 is ∼2-fold higher. Endothelial, Kupffer and parenchymal cells accounted for 45.7 ± 5.7, 33.0 ± 5.9 and 21.3 ± 2.6% of the liver uptake of [3H]ISIS-9388, respectively, and intracellular concentrations of ∼2, 75 and 50 µM, respectively, could be reached in these cells (1 mg/kg dose). Preinjection with polyinosinic acid or poly­adenylic acid reduced the hepatic uptake of [3H]ISIS-9388, which suggests the involvement of (multiple) scavenger receptors. Size exclusion chromatography of mixtures of the oligonucleotides and rat plasma indicated that ISIS-9388 binds to a larger extent to high molecular weight proteins than ISIS-3082. Analysis by agarose gel electrophoresis indicated that ISIS-9388 binds more tightly to plasma proteins than ISIS-3082. The different interaction of the oligonucleotides with plasma proteins possibly explains their different dispositions. We conclude that cholesterol conjugation results in high accumulation of phosphorothioate oligodeoxynucleotides in various liver cell types, which is likely to be beneficial for antisense therapy of liver-associated diseases.

Documentos Relacionados

• In vivo fate of phosphorothioate antisense oligodeoxynucleotides: predominant uptake by scavenger receptors on endothelial liver cells.
• Binding, uptake, and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides.
• Sequence-independent inhibition of in vitro vascular smooth muscle cell proliferation, migration, and in vivo neointimal formation by phosphorothioate oligodeoxynucleotides.
• Nucleocytoplasmic shuttling: a novel in vivo property of antisense phosphorothioate oligodeoxynucleotides
• In vivo inhibition of duck hepatitis B virus replication and gene expression by phosphorothioate modified antisense oligodeoxynucleotides.